CG Oncology/$CGON
1D1W1MYTD1Y5YMAX
Capital at risk
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
- Ticker
- $CGON
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Dallas, United States
- Website
- cgoncology.com
CG Oncology Metrics
BasicAdvanced
$6.9B
-
-$2.72
0.24
-
Price and volume
Market cap
$6.9B
Beta
0.24
52-week high
$80.97
52-week low
$35.64
Average daily volume
766K
Financial strength
Current ratio
22.219
Quick ratio
21.776
Long term debt to equity
0.008
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-249.663
Gross margin (TTM)
-2,593.69%
Net profit margin (TTM)
-3,602.68%
Operating margin (TTM)
-4,056.18%
Management effectiveness
Return on assets (TTM)
-17.67%
Return on equity (TTM)
-26.41%
Valuation
Price to revenue (TTM)
1,035.108
Price to book
6.71
Price to tangible book (TTM)
6.79
Price to free cash flow (TTM)
-35.946
Free cash flow yield (TTM)
-2.78%
Free cash flow per share (TTM)
-2.177
Growth
Revenue change (TTM)
1,030.31%
Earnings per share change (TTM)
53.47%
What the Analysts think about CG Oncology
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
Analyst projections of the future price of CG Oncology stock.
Bulls say / Bears say
Peer-reviewed Phase 3 BOND-003 data show a 75.5% complete-response rate, with responses lasting in 64.2% of patients at 12 months and 60.1% at 24 months. This supports cretostimogene as a potentially durable bladder-sparing treatment in a difficult, BCG-unresponsive population. (CG Oncology, UroToday)
The company has several near-term value catalysts: PIVOT-006 topline data are expected soon and completion of the first BLA for high-risk BCG-unresponsive disease is targeted for the fourth quarter of 2026. Fast Track and Breakthrough Therapy designations, alongside completed clinical and non-clinical BLA modules, support a relatively advanced regulatory position. (CG Oncology, The Biotech Times)
Around $1.0 billion of cash, cash equivalents and marketable securities is expected by management to fund operations through 2029. That gives CG Oncology time to complete trials, finish regulatory work and prepare for launch without an immediate dependence on favourable capital markets. (CG Oncology, StockTitan)
PIVOT-006 is an event-driven, randomised test that remains a major binary risk, with topline results still only expected in the near term. Positive single-arm BOND-003 results may not translate if the surveillance control performs better than expected. (Investing.com, CG Oncology)
CG Oncology is still loss-making and has no approved product generating meaningful sales. Q2 net loss was $79.1 million, while first-half operating cash outflow reached $103.4 million, so a prolonged regulatory or launch delay could bring further equity issuance and dilution despite the current cash buffer. (StockTitan, Simply Wall St)
Approval and commercial adoption are not assured. The company still has manufacturing and inspection work tied to the BLA, while existing approved options and a changing bladder-cancer treatment landscape mean cretostimogene must prove its label, competitive efficacy and real-world uptake. (The Biotech Times, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.
CG Oncology Financial Performance
Revenues and expenses
CG Oncology Earnings Performance
Company profitability
Upcoming events
No upcoming events
CG Oncology News
AllArticlesVideos
Funds containing CG Oncology
AllUSDEURGBP
Fund name | Fund size | $CGON weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.55% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.55% |
iShares Healthcare Innovation£DRDR | £1B | 0.55% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.44% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.44% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.